K. D. Rysenkova – Post-graduate Student, Faculty of Medicine, Lomonosov Moscow State University  E-mail: karina_ry@mail.ru

E. V. Semina – Ph.D. (Biol.), Leading Research Scientist, Federal State Budget Organization National Medical Research Center of Cardiology of the Ministry of Healthcare of the Russian Federation; Senior Research Investigator, Faculty of Medicine, Lomonosov Moscow State University

E-mail: e-semina@yandex.ru

M. N. Karagyaur – Ph.D. (Biol.), Senior Research Scientist, Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University 

E-mail: darth_max@mail.ru 

А. А. Shmakova – Student, Faculty of Medicine, Lomonosov Moscow State University

E-mail: anya.shmakova@list.ru

D. T. Dyjkanov – Leading Specialist, Faculty of Medicine, Lomonosov Moscow State University

E-mail: danidy@inbox.ru

K. А. Rubina – Dr.Sc. (Biol.), Senior Research Scientist, Faculty of Medicine, Lomonosov Moscow State University

E-mail: rkseniya@mail.ru 

V. А. Tkachuk – Academician RAS, Dr.Sc. (Biol.), Professor, Federal State Budget Organization 

National Medical Research Center of Cardiology of the Ministry of Healthcare of the Russian Federation; Dean of Faculty of Medicine, Lomonosov Moscow State University

E-mail: tkachuk@fbm.msu.ru

In was selected guide RNA cequences to suppress the expression of the urokinase

receptor gene (PLAUR) in neuroblastoma cells Neuro2a using genome

editing CRISPR/Cas9 technology. It was found that suppression of the

PLAUR gene decreases the invasive potential of neuroblastoma, which is

normally stimulated by urokinase – the endogenous ligand of the urokinase

receptor.

1. Gatta G., Botta L., Rossi S., Aareleid T., Bielska-Lasota M., Clavel J., Dimitrova N., Jakab Z., Kaatsch P., Lacour B., Mallone S., MarcosGragera R., Minicozzi P., Sánchez-Pérez M. J., Sant M., Santaquilani M., Stiller C., Tavilla A., Trama A., Visser O., Peris-Bonet R., Group E. W. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study // Lancet Oncol. 2014. V. 15.  № 1. P. 35–47.
2. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma // Nat. Rev. Cancer. 2003. V. 3. № 3. P. 203–16.
3. Brodeur G.M., Bagatell R. Mechanisms of neuroblastoma regression // Nat. Rev. Clin. Oncol. 2014. V. 11. № 12. P. 704–13.
4. DuBois S.G., Kalika Y., Lukens J.N., Brodeur G.M., Seeger R.C., Atkinson J.B., Haase G.M., Black C.T., Perez C., Shimada H., Gerbing R., Stram D.O., Matthay K.K. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival // J. Pediatr. Hematol. Oncol. 1999. V. 21. № 3. P. 181–9.
5. Li P., Gao Y., Ji Z., Zhang X., Xu Q., Li G., Guo Z., Zheng B., Guo X. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma // J. Pediatr. Surg. 2004. V. 39. № 10. P. 1512–9.
6. Yang J.L., Seetoo D., Wang Y., Ranson M., Berney C.R., Ham J.M., Russell P.J., Crowe P.J. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets // Int. J. Cancer. 2000. V. 89. № 5. P. 431–9.
7. Yu W., Kim J., Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy // J. Cell. Biol. 1997. V. 137. № 3. P. 767–77.
8. Swiercz R., Wolfe J.D., Zaher A., Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype // Clin. Cancer. Res. 1998. V. 4. № 4. P. 869–77.
9. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR // Nat. Rev. Mol. Cell. Biol. 2010. V. 11. № 1. P. 23–36.
10. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D. A., Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes // Science. 2007. V. 315. № 5819. P. 1709–12.
11. Wu Y., Liang D., Wang Y., Bai M., Tang W., Bao S., Yan Z., Li D., Li J. Correction of a genetic disease in mouse via use of CRISPR-Cas9 // Cell. Stem. Cell. 2013. V. 13. № 6. P. 659–62.
12. https://www.lgcstandards-atcc.org/products/ all/CCL-131.aspx?geo_country=ru (data obrashheniya k resursu: 04.12.17)
13. Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., Scott D.A., Inoue A., Matoba S., Zhang Y., Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity // Cell. 2013. V. 154. № 6. P. 1380–9.
14. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas. systems // Science. 2013. V. 339. № 6121. P. 819–23.
15. http://CRISPR/Cas9.mit.edu/ (data obrashheniya k resursu: 04.12.17)
16. Beloglazova I.B., Akopyan Zh.A., Karagyaur M.N., Plexanova O.S., Syomina E.V., Stambol'skij D.V. Perspektivy' sozdaniya protivoopuxolevy'x lekarstvenny'x sredstv, napravlenny'x na sistemu aktivatora plazminogena urokinaznogo tipa // Texnologii zhivy'x sistem. 2013. T. 10. № 1. C. 003–019.
17. Tam C., Wong J.H., Cheung R.C. F., Zuo T., Ng T.B. Therapeutic potentials of short interfering RNAs // Appl. Microbiol. Biotechnol. 2017. V. 101. № 19. P. 7091–7111.
18. Young S.W., Stenzel M., Yang J.L. Nanoparticle-siRNA: A potential cancer therapy? // Crit. Rev. Oncol. Hematol. 2016. V. 98. P. 159–69.
19. Maduri S. Applicability of RNA interference in cancer therapy: Current status // Indian. J. Cancer. 2015. V. 52. № 1. P. 11–21.
20. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C., Rao J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas // J. Biol. Chem. 2005. V. 280. № 23. P. 21882–92.
21. Mohan P.M., Chintala S.K., Mohanam S., Gladson C.L., Kim E.S., Gokaslan Z.L., Lakka S.S., Roth J.A., Fang B., Sawaya R., Kyritsis A.P., Rao J.S. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth // Cancer Res. 1999. V. 59. № 14. P. 3369–73.
22. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R., Rao J.S. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas // Cancer Res. 2004. V. 64. № 12. P. 4069–77.
23. Lakka S.S., Rajagopal R., Rajan M.K., Mohan P.M., Adachi Y., Dinh D.H., Olivero W.C., Gujrati M., Ali-Osman F., Roth J.A., Yung W.K., Kyritsis A.P., Rao J.S. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines // Clin. Cancer Res. 2001. V. 7. № 4. P. 1087–93.
24. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., Wolfsberg T.G., Umayam L., Lee J.C., Hughes C.M., Shanmugam K.S., Bhattacharjee A., Meyerson M., Collins F.S. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells // Proc. Natl. Acad. Sci. USA. 2004. V. 101. № 7. P. 1892–7.
25. Nemudry'j A.A., Valetdinova K.R., Medvedev S.P., Zakiyan S.M. Sistemy' redaktirovaniya genomov TALEN i CRISPR/CAS instrumenty' otkry'tij // Acta Naturae. 2014. T. 3. № 22. C. 20–42.
26. Cui Y., Wu B.O., Flamini V., Evans B.A. J., Zhou D., Jiang W.G. Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells // Anticancer. Res. 2017. V. 37. № 8. P. 4415–4424.
27. Wang H., Sun W. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation // Cancer Lett. 2017. V. 385. P. 137–143.